James Maxwell Rennie

James Maxwell Rennie is a notable inventor based in London, GB. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of injectable formulations. With a total of 2 patents to his name, Rennie's work focuses on innovative solutions for psychiatric and neurological disorders.

Latest Patents

Rennie's latest patents involve injectable formulations that comprise a salt of an optionally substituted dimethyltryptamine compound, a buffer, and water. These formulations are designed to have pH values ranging from about 3.5 to about 6.5 and osmolalities of approximately 250 to about 350 mOsm/Kg. The stability and clinical acceptability of these formulations make them suitable for injection, with potential applications in treating various psychiatric or neurological disorders.

Career Highlights

Throughout his career, James Maxwell Rennie has worked with companies such as Small Pharma Ltd and Cybin UK Ltd. His expertise in pharmaceutical formulations has positioned him as a key player in the industry, contributing to advancements in treatment methodologies.

Collaborations

Rennie has collaborated with professionals in the field, including his coworker Marie Claire Layzell. These partnerships have further enhanced his innovative work in pharmaceutical formulations.

Conclusion

James Maxwell Rennie's contributions to the field of pharmaceutical formulations highlight his commitment to advancing medical treatments. His innovative injectable formulations have the potential to significantly impact the treatment of psychiatric and neurological disorders.

This text is generated by artificial intelligence and may not be accurate.